Abstract:In this study we investigated gene silencing by RNA interference (RNAi) as a potential therapy for Spinocerebellar ataxia type 1 (SCA1), a dominant neurodegenerative disease caused by expansion of a polyglutamine tract in ataxin-1. Therapies for SCA1 do not exist, and studies in mouse models of other polyglutamine repeat diseases support that silencing of the disease allele can improve disease manifestations. Short hairpin RNAs (shRNAs) specific to SCA1 were screened for effective silencing against a mutant human ataxin (Q = 82) in vitro prior to testing in a transgenic mouse model of SCA1. SCA1 trangenic mice express a mutant human ataxin-1 (Q = 82) from the Purkinje cell specific promoter, and recapitulate many aspects of human SCA1, including progressive ataxia, shrinkage of the molecular layer, Purkinje cell degeneration and nuclear inclusion formation. AAV1 vectors expressing the most effective shRNA and an hrGFP reporter (AAVshSCA1.hrGFP) were injected into the cerebellar lobules of 7-week old SCA1 or wildtype mice. Viruses expressing an irrelevant hairpin (AAVshlacZ.hrGFP), or saline, were included as hairpin and injection controls. Rotarod tests of motor coordination were done 2-week prior and every two weeks following injections, until sacrifice at 16 weeks of age. Beginning at 9 weeks of age and continuing until sacrifice, SCA1 mice treated with shSCA1-expressing viruses showed significantly improved performance on the rotarod relative to saline- or shlacZ-treated SCA1 mice. There was no effect of the therapy on the performance of wildtype mice. The efficiency of transduction, quantified by hrGFP expression, ranged from 5–10% of all Purkinje cells. We took advantage of hrGFP reporter expression to directly compare transduced and untransduced lobules for ataxin-1 nuclear inclusions, Purkinje cell morphology, and the width of the cerebellar molecular layer. In shSCA-treated SCA1 mice, Purkinje cell dendritic arbors remained robust, and transduced lobules (hrGFP+) had molecular layer widths indistinguishable from those of wild-type mice. Moreover, ataxin-1 inclusions were notably absent from all hrGFP-positive Purkinje cells in shSCA1-treated SCA1 mice (0 inclusions in 400 cells). In contrast, 49% of Purkinje cells from shlacZ-treated mice had inclusions, similar to untreated 16-wk old SCA1 mice. These data provide the first in vivo demonstration of efficacy of RNAi for dominant neurodegenerative disease therapy.

RNAi Suppresses Polyglutamine-Induced Neurodegeneration in a Model of Spinocerebellar Ataxia

717. RNAi Therapy for Dominant Neurodegenerative Diseases

AAV-Mediated CAG-Targeting Selectively Reduces Polyglutamine-Expanded Protein and Attenuates Disease Phenotypes in a Spinocerebellar Ataxia Mouse Model

Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

207. Micro RNAs as Novel siRNA Shuttles

Treatment of neurologic pathology and inflammation in Machado-Joseph disease through in vivo self-assembled siRNA

Cas9 editing of ATXN1 in a spinocerebellar ataxia type 1 mice and human iPSC-derived neurons

Allele-specific Silencing of Dominant Disease Genes.

Cerebellum-Enriched Protein Inpp5a Contributes To Selective Neuropathology In Mouse Model Of Spinocerebellar Ataxias Type 17

Single nuclei RNA sequencing investigation of the Purkinje cell and glial changes in the cerebellum of transgenic Spinocerebellar ataxia type 1 mice

AAV-based delivery of RNAi targeting Ataxin-2 improves survival, strength, and pathology in mouse models of rapidly and slowly progressive sporadic ALS

DNAzyme Cleavage of CAG Repeat RNA in Polyglutamine Diseases

An RNA-targeting CRISPR–Cas13d system alleviates disease-related phenotypes in Huntington’s disease models

RNA Interference Gene Therapy in Dominant Retinitis Pigmentosa and Cone-Rod Dystrophy Mouse Models Caused by GCAP1 Mutations

Neuronal expression of TATA box-binding protein containing expanded polyglutamine in knock-in mice reduces chaperone protein response by impairing the function of nuclear factor-Y transcription factor.

Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy.

Cas9-mediated replacement of expanded CAG repeats in a pig model of Huntington's disease

Cas9-mediated Replacement of Expanded CAG Repeats in a Pig Model of Huntington’s Disease

Single-nuclei RNA sequencing uncovers non-cell autonomous changes in cerebellar astrocytes and oligodendrocytes that may contribute to Spinocerebellar Ataxia Type 1 (SCA1) pathogenesis

Cerebellar Transcriptome Profiles of ATXN1 Transgenic Mice Reveal SCA1 Disease Progression and Protection Pathways

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease